
Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy/Economic_IndiaTimes
Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy
In the intricate realm of biotech, Eyestem Research stands at the forefront, navigating a challenging path towards regulatory approval. The recently submitted Investigational New Drug (IND) application to the Central Drugs Standards Control Organization, India (CDSCO) marks a pivotal moment for Eyestem’s therapy, Eyecyte-RPE. This groundbreaking treatment aims to address medium- and late-stage geographic atrophy, secondary to dry AMD, providing hope for patients.
Global Regulatory Landscape: A Balancing Act
Jogin Desai, CEO of Eyestem Research, sheds light on the complex dance with global regulatory agencies. Harmonization efforts are underway, with common technical documents acting as beacons across India, Australia, and Singapore. Desai emphasizes the importance of understanding each country’s unique regulatory nuances, be it India’s stringent input controls or Australia’s reliance on output controls.
The Rigorous Path to Clinical Stage: From Idea to Approval
Desai unravels the intricate lifecycle of a biotech company, detailing the rigorous journey from ideation to clinical-stage readiness. Animal trials, proof of concept, efficacy studies, and toxicity assessments constitute the arduous path. IND approval signifies a company’s maturity, signaling to investors and paving the way for impactful biotech solutions.
As Eyestem aims for IND approval, its CEO envisions a future where the company addresses not only dry AMD but also Parkinson’s and retinitis pigmentosa. With a commitment to affordability, Eyestem strives to revolutionize the cost paradigm in cell and gene therapies, offering a beacon of hope for patients globally.
In collaboration with renowned institutions like AIIMS in Delhi and LV Prasad Eye Institute, Eyestem Research propels regenerative therapies forward, setting new standards in ophthalmology. Beyond its immediate impact, this partnership hints at the transformative role Eyestem may play in the evolution of personalized and regenerative medicine.
Latest Posts
- Solmate Infrastructure Plans to Expand into Global AI Compute with a GPU-as -a-Service asset-light Model 16 Nov 2026
- Estonia-Russia border closed From December 1 After Foiled Arson Attack on Drone Factory16 Nov 2026
- Amazon Loses 40 Satellites After Vulcan Rocket Fails During Launch16 Nov 2026
- What Did Former Pakistan PM Imran Khan Tell Pakistan’s Top Judges About His Health16 Nov 2026
- West Bengal Moves Supreme Court Against Calcutta High Court Stay on Kolkata Municipal Corporation Elections16 Nov 2026
- Adani Group Begins Production Of India’s Longest Wind Turbine Blade At Mundra16 Nov 2026
- Xi Jinping, Donald Trump and Vladimir Putin to Hold First Trilateral Summit in Shenzhen – China on November 1916 Nov 2026
- Encounter Breaks Out in Kulgam, Jammu Kashmir After Security Forces Launch Search Operation16 Nov 2026
- High Court Seeks Time-Bound Plan to Fill 6,775 Health Department Vacancies In Jammu Kashmir16 Nov 2026
- Iran Learning From Last War, Moving Towards Major Cyber Operations !!15 Nov 2026
